Abstract
AbstractBACKGROUNDHypoglycemia is the principle adverse effect of sulfonylurea, especially in patients with renal failure. Conventional treatment consists of hypertonic dextrose, sometimes combined with glucagon. However, paradoxically both agents can stimulate insulin secretion and induce rebound hypoglycemia.PATIENTWe present the case of a hemodialysis patient with relapsing gliclazide‐induced hypoglycemia in the context of sepsis.RESULTSOur patient failed to respond to regular infusions of hypertonic dextrose and oral carbohydrates. His hypoglycemia only resolved after a single dose of octreotide. The pathophysiology of recurrent sulfonylurea‐induced hypoglycemia and the challenges of current therapies are discussed. The somatostatin analogue octreotide inhibits insulin release and has been proposed as an antidote for sulfonylurea overdose.CONCLUSIONSWe propose that octreotide has a clinical role in the treatment of patients with renal failure and sulfonylurea‐ induced hypoglycemia.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
